Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 2, 2000, Pages 175-182

  De Mitrio, Vito ^a   Marino, R ^a   Cicinelli, E ^a   Galantino, P ^a   Di Bari, L ^a   Giannoccaro, F ^a   De Pergola, G ^a   Lapecorella, M ^a   Schonauer, S ^a   Schiraldi, O ^a  

^a NONE

Author keywords

Activated protein C sensitivity; Activated protein C resistance; Estradiol; Factor VIII; Hormone replacement therapy; Von Willebrand factor

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8C; ESTRADIOL; PLASMA PROTEIN; PROTEIN C; PROTEIN S; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0033993866     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200003000-00009     Document Type: Article

References (35)

1. 1. Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-1072.
2. 2 Walker FJ, Chavin S, Fay PJ. Inactivation of FVIII by activated protein C and protein S. Arch Biochem Biophys 1987; 252: 322-328.
3. 3 Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236-1243.
4. 4 Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309: 340-344.
5. 5 Comp PC, Nixon RR, Cooper R, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088.
6. 6 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
7. 7 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
8. 506Q is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-488.
9. 9 Bertina RM. Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997; 78: 478-482.
10. 10 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-834.
11. 11 Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
12. 12 Trossaert M, Conard J, Horellon MH, Samama MM, Ireland H, Bayston TA, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709 [Letter].
13. 13 Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haemost 1997; 78: 765-769.
14. 14 Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage form of 17 β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106.
15. 15 De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, et al. Biological effects of estradiol 17-β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metabol 1986; 62: 536-541.
16. 16 Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, et al. Biological effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
17. 17 De Mitrio V, Marino R, Giannoccaro F, Galantino P, Cicinelli E. Improved sensitivity to activated protein C following postmenopausal hormone replacement therapy. Blood Coag Fibrinol 1998; 9: 293-294.
18. 18 De Mitrio V, Marino R, Scaraggi FA, Di Bari L, Giannoccaro F, Petronelli M, et al. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. Blood Coag Fibrinol 1999; 10: 409-416
19. 19 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-326.
20. 20. Østerud B, Robertsen R, Asvang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coag Fibrinol 1994; 5: 853-854.
21. 21 Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-470.
22. 22 Henkens CMA, Born VJJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-404.
23. 23 Henkens CMA, Born VJJ, Seinen AJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-1199.
24. 24 Koster K, Blann AD, Briet E, Vanderbrouke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
25. 25 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coag Fibrinol 1996; 7: 761-765.
26. 26 de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-1276
27. 27 Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-828.
28. 28 Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
29. 29 Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201-1209.
30. 30 The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 75: 476-480.
31. 31 Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-423.
32. 32 Marcucci R, Abbate R, Fedi S, Gori AM, Brunelli T, Bruni V, et al. Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels. Am J Clin Pathol 1999; 111: 769-772.
33. 33 Lenting PJ, Neels JG, van Den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 23734-23739.
34. 34 Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Biol Chem 1998; 379: 951-964.
35. 35 Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 1999; 274: 31305-31311.